MX2020011323A - Composicion farmaceutica para liberacion controlada de treprostinil. - Google Patents

Composicion farmaceutica para liberacion controlada de treprostinil.

Info

Publication number
MX2020011323A
MX2020011323A MX2020011323A MX2020011323A MX2020011323A MX 2020011323 A MX2020011323 A MX 2020011323A MX 2020011323 A MX2020011323 A MX 2020011323A MX 2020011323 A MX2020011323 A MX 2020011323A MX 2020011323 A MX2020011323 A MX 2020011323A
Authority
MX
Mexico
Prior art keywords
treprostinil
controlled release
pharmaceutical composition
pharmaceutical compositions
phospholipid
Prior art date
Application number
MX2020011323A
Other languages
English (en)
Inventor
Pei Kan
Yi Fong Lin
Ko Chieh Chen
Original Assignee
Pharmosa Biopharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmosa Biopharm Inc filed Critical Pharmosa Biopharm Inc
Publication of MX2020011323A publication Critical patent/MX2020011323A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5578—Eicosanoids, e.g. leukotrienes or prostaglandins having a pentalene ring system, e.g. carbacyclin, iloprost
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1277—Processes for preparing; Proliposomes
    • A61K9/1278—Post-loading, e.g. by ion or pH gradient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Dispersion Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Otolaryngology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Se proporcionan en la presente composiciones farmacéuticas que contienen (a) por lo menos un liposoma que incluye por lo menos un fosfolípido formador de vesícula; y (b) treprostinil encapsulado dentro del liposoma. La relación de treprostinil a fosfolípido es igual a o más alta que 0.035 y proporciona una liberación controlada de treprostinil. También se proporciona el uso de las composiciones farmacéuticas para tratar enfermedades respiratorias.
MX2020011323A 2018-05-07 2019-05-06 Composicion farmaceutica para liberacion controlada de treprostinil. MX2020011323A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862667889P 2018-05-07 2018-05-07
US201862670875P 2018-05-14 2018-05-14
PCT/US2019/030841 WO2019217271A1 (en) 2018-05-07 2019-05-06 Pharmaceutical composition for controlled release of treprostinil

Publications (1)

Publication Number Publication Date
MX2020011323A true MX2020011323A (es) 2020-11-18

Family

ID=68384347

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2020011323A MX2020011323A (es) 2018-05-07 2019-05-06 Composicion farmaceutica para liberacion controlada de treprostinil.
MX2023011701A MX2023011701A (es) 2018-05-07 2020-10-26 Composicion farmaceutica para liberacion controlada de treprostinil.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2023011701A MX2023011701A (es) 2018-05-07 2020-10-26 Composicion farmaceutica para liberacion controlada de treprostinil.

Country Status (13)

Country Link
US (3) US11229616B2 (es)
EP (1) EP3790554A4 (es)
JP (1) JP7140418B2 (es)
KR (2) KR20230170124A (es)
CN (1) CN112384224B (es)
AU (1) AU2019266171B2 (es)
BR (1) BR112020020127A2 (es)
CA (1) CA3099411A1 (es)
IL (1) IL278513B (es)
MX (2) MX2020011323A (es)
SG (1) SG11202011045VA (es)
TW (1) TWI696471B (es)
WO (1) WO2019217271A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL278513B (en) 2018-05-07 2022-09-01 Pharmosa Biopharm Inc A pharmaceutical preparation for the controlled release of treprostinil
AU2020274094B2 (en) * 2019-05-14 2023-08-31 Pharmosa Biopharm Inc. Pharmaceutical composition of a weak acid drug and methods of administration
WO2024067849A1 (zh) * 2022-09-30 2024-04-04 上海济煜医药科技有限公司 一种脂质体药物组合物及其制备方法和应用
WO2024067840A1 (zh) * 2022-09-30 2024-04-04 上海济煜医药科技有限公司 一种脂质体及其制备方法和应用

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5082664A (en) * 1987-05-22 1992-01-21 The Liposome Company, Inc. Prostaglandin-lipid formulations
IL91664A (en) * 1988-09-28 1993-05-13 Yissum Res Dev Co Ammonium transmembrane gradient system for efficient loading of liposomes with amphipathic drugs and their controlled release
AU4981896A (en) * 1995-02-14 1996-09-04 Sequus Pharmaceuticals, Inc. Liposome composition and method for administering liposome-loadable drugs
DE69632859T2 (de) 1995-04-18 2005-07-14 Yissum Research Development Company Of The Hebrew University Of Jerusalem Verfahren zur Arzneistoffbehandlung von Liposomen Zusammensetzung
AU2003298738A1 (en) * 2002-11-26 2004-06-18 Su-Ming Chiang Liposomal formulations
CN102697790A (zh) * 2003-05-22 2012-10-03 联合治疗公司 化合物和释放前列环素类似物的方法
US7744920B2 (en) 2004-09-09 2010-06-29 Hadasit Medical Research Services & Development Limited Use of liposomal glucocorticoids for treating inflammatory states
WO2007049279A2 (en) * 2005-10-26 2007-05-03 Yissum Research Development Company Of The Hebrew University Of Jerusalem A liposomal combination and uses thereof
AU2006307460A1 (en) 2005-10-26 2007-05-03 New York University A method for preparing liposomes and uses thereof
WO2007134292A2 (en) * 2006-05-15 2007-11-22 United Therapeutics Corporation Treprostinil administration using a metered dose inhaler
CN102164487A (zh) * 2008-09-25 2011-08-24 阿拉迪姆公司 曲前列素的深肺部递送
AU2009302042A1 (en) * 2008-10-07 2010-04-15 Yissum Research Development Company Of The Hebrew University Of Jerusalem, Ltd. Liposomal systems comprising sphingomyelin
WO2010096242A1 (en) * 2009-02-18 2010-08-26 Aradigm Corporation Ph-modulated formulations for pulmonary delivery
CN101703471B (zh) * 2009-11-18 2011-08-10 中国药科大学 一种改良的硫酸铵梯度法制备脂质体的方法
WO2011092708A2 (en) * 2010-02-01 2011-08-04 Yissum Research Development Company Of The Hebrew University Of Jerusalem, Ltd. Liposomes comprising amphipathic drugs and method for their preparation
CA2890219A1 (en) 2012-11-30 2014-06-05 Insmed Incorporated Prostacylin compositions and methods for using the same
EP3388055B1 (en) 2015-12-08 2021-11-17 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Method for preparing liposome
TWI754659B (zh) 2016-08-08 2022-02-11 台灣微脂體股份有限公司 用於製備含有弱酸性劑之微脂體組合物的傳輸載體、方法及套組
CN111372580A (zh) 2017-07-24 2020-07-03 国邑药品科技股份有限公司 包含弱酸药物的脂质体组合物及其用途
IL278513B (en) 2018-05-07 2022-09-01 Pharmosa Biopharm Inc A pharmaceutical preparation for the controlled release of treprostinil

Also Published As

Publication number Publication date
CA3099411A1 (en) 2019-11-14
JP2021523157A (ja) 2021-09-02
US11833125B2 (en) 2023-12-05
KR20230170124A (ko) 2023-12-18
TWI696471B (zh) 2020-06-21
KR102610141B1 (ko) 2023-12-05
EP3790554A4 (en) 2022-03-30
US11229616B2 (en) 2022-01-25
IL278513A (es) 2020-12-31
JP7140418B2 (ja) 2022-09-21
AU2019266171B2 (en) 2021-10-28
CN112384224A (zh) 2021-02-19
MX2023011701A (es) 2023-10-19
CN112384224B (zh) 2024-06-07
SG11202011045VA (en) 2020-12-30
US20240050387A1 (en) 2024-02-15
TW201946614A (zh) 2019-12-16
WO2019217271A1 (en) 2019-11-14
KR20200140329A (ko) 2020-12-15
US20190336461A1 (en) 2019-11-07
AU2019266171A1 (en) 2020-11-26
BR112020020127A2 (pt) 2021-01-05
EP3790554A1 (en) 2021-03-17
IL278513B (en) 2022-09-01
US20220047537A1 (en) 2022-02-17

Similar Documents

Publication Publication Date Title
MX2023011701A (es) Composicion farmaceutica para liberacion controlada de treprostinil.
MX2020013853A (es) Compuestos innovadores.
WO2020086759A3 (en) Composition and method for treating the lungs
PA8780201A1 (es) Derivados de pirasol sustituidos con heteroaril utiles para tratar trastornos hiperproliferativos y enfermedades asociadas con angiogénesis
BR112018014545A2 (pt) probióticos para uso como agentes anti-inflamatórios na cavidade oral
MY175305A (en) Proliposomal testosterone formulations
CR20190433A (es) Compuestos de pirimidinil-pyridiloxi-naftil y métodos para tratar enfermedades y trastornos relacionados con ire1
PH12020500543A1 (en) Nonracemic mixtures and uses thereof
PH12017502040A1 (en) Oral care composition comprising calcium silicate
CR20220215A (es) Heteroaril bifenil amidas para el tratamiento de enfermedades relacionadas con el ligando pd-l1
MX2018008903A (es) COMPOSICIONES Y METODOS DE USO DE ß-HIDROXI-ß-METILBUTIRATO (HMB) PARA MODULAR AUTOFAGIA Y LIPOFAGIA.
PH12015500611B1 (en) Oral care composition
MX2022001449A (es) Compuestos de aminoesterol humano ent-03, composiciones relacionadas que comprenden los mismos y metodos para usar los mismos.
MX2021014774A (es) Formulaciones de liberacion modificada y usos de las mismas.
MX2021007177A (es) Formulacion de inhalacion de polvo seco y su uso para el tratamiento terapeutico de los pulmones.
PH12019500690A1 (en) Oral care composition
MX2020014262A (es) Composicion farmaceutica que comprende un agente basico poco soluble.
MX2019015005A (es) Proceso para la preparación de composición estandarizada de arjunglucósido de la corteza de terminalia arjuna.
GB2564801A (en) Implantable scaffolds for treatment of sinusitis
MX2021005910A (es) Formulacion de proteina de alta concentracion.
MX2021009443A (es) Composiciones que contienen bacterias productoras de bacillaeno o preparaciones de las mismas.
AR066936A1 (es) 3 - (2r - tetrahidrofuril - metil) - 2 - tioxantina. composiciones farmaceuticas.
PH12019501820A1 (en) Pharmaceutical compositions for combination therapy
MX2022002185A (es) Composicion farmaceutica acuosa de anticuerpo anti-pd1 prolgolimab y su uso.
MX2022012964A (es) Forma de dosificacion oral solida que comprende pomalidomida.